Evidence tracker Pharmacology Delirium prevention

Dexmedetomidine to prevent postoperative delirium

Does perioperative dexmedetomidine prevent delirium, and in whom? Compare dosing and timing, cardiac versus noncardiac surgery, and delirium outcomes alongside bradycardia and hypotension.

Indexed papers
19
matching, retractions excluded
Randomized trials
4
plus 2 meta-analyses
With AI summary
19
others show original abstract
Registered, not results
0
ongoing trials
Clinical assessment not completed. No bottom line, certainty grade, or curated effect sizes have been written for this topic. Below is a source-linked inventory of matching papers (up to 200 from our cache), not a systematic review. Read the original studies before drawing conclusions.

Published studies

Open in feed

Recent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.

Showing 8 of 19 · Review

Recent evidence · past year

  1. Review Eur Heart JPublished 6 Nov 2026 Cekaj E et al.
    Delirium in cardiovascular medicine.
    AI summary of the abstract, unverified
    • This state-of-the-art review covers delirium epidemiology, mechanisms, diagnosis, prevention and treatment across cardiovascular medicine, drawing on interdisciplinary expert input.
    • It identifies risk factors such as advanced age, baseline cognitive impairment, cerebrovascular disease, longer operative times, complications and systemic inflammation.
    • Non-pharmacological multicomponent prevention is described as strongly supported, while preventive pharmacologic use remains controversial; dexmedetomidine is noted for ICU settings.
    • The authors conclude that systematic risk assessment and multimodal prevention should be standard care, with more high-quality studies needed for cardiovascular-specific guidelines.
    Original abstract (PubMed)

    Delirium is a common yet underrecognized neuropsychiatric syndrome in cardiovascular medicine associated with prolonged hospitalization, increased mortality, and long-term cognitive decline. Patients undergoing interventional or surgical cardiovascular procedures-such as transcatheter aortic valve replacement, surgical aortic valve replacement, coronary artery bypass grafting, or percutaneous coronary interventions-may be particularly vulnerable to its development. Delirium incidence varies widely across cardiovascular procedures, influenced by patient characteristics, procedural invasiveness, and diagnostic methodology. Risk factors include advanced age, baseline cognitive impairment, cerebrovascular disease, extended operative times, perioperative complications, and systemic inflammation. Diagnostic tools such as the Confusion Assessment Method (CAM) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) score are established but underutilized in the diagnosis of delirium. While preventive strategies emphasizing non-pharmacological, multicomponent approaches-such as early mobilization, cognitive stimulation, and sleep hygiene-are supported by strong evidence, preventive use of pharmacologic agents remains controversial. Pharmacologic treatment is reserved for select cases; dexmedetomidine shows benefits in intensive care unit settings, while antipsychotics like quetiapine and risperidone may be used cautiously. Overall, delirium poses a significant clinical challenge in cardiovascular medicine and requires a proactive, interdisciplinary approach. Systematic risk assessment and multimodal preventive strategies should be the standard of care, while pharmacologic treatment should be symptom- and context-specific. Further high-quality studies are needed to inform evidence-based guidelines tailored to cardiovascular populations. The present state-of-the-art review summarizes the current literature on the epidemiology, mechanisms, clinical manifestations, diagnosis, prevention, and treatment of delirium in cardiovascular medicine. By integrating findings and interdisciplinary expert discussions from interventional cardiology, cardiac surgery, and psychiatry, it aims to define the unique vulnerability of this patient population, highlight critical knowledge gaps, and lay the foundation for developing targeted, evidence-based management strategies.

  2. Review Eur Geriatr MedPublished 30 Oct 2026 Shi CG et al.
    Effects of perioperative dexmedetomidine on postoperative delirium in older surgical patients: an updated meta-analysis of randomized controlled trials.
    AI summary of the abstract, unverified
    • Meta-analysis of 22 RCTs including 4161 older surgical patients under general anesthesia, searched across PubMed, Embase and CENTRAL through July 2026.
    • Compared perioperative intravenous dexmedetomidine with control for prevention of postoperative delirium, the primary outcome.
    • Dexmedetomidine reduced postoperative delirium (RR 0.56, 95% CI 0.47 to 0.66; P<0.00001; I² 24%) and PONV (RR 0.79, 95% CI 0.62 to 0.99; P=0.04).
    • Dexmedetomidine was associated with more intraoperative and postoperative bradycardia and more intraoperative hypotension.
    Original abstract (PubMed)

    STUDY OBJECTIVE: To evaluate the efficacy of perioperative intravenous dexmedetomidine in preventing postoperative delirium (POD) in older surgical patients. METHODS: A comprehensive literature search was performed across three authoritative databases: PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to July 7, 2026, included all available RCTs evaluating the effect of dexmedetomidine on POD in older surgical patients undergoing general anesthesia. The primary outcome was the incidence of POD. Secondary outcomes encompassed adverse events, including PONV, intraoperative and postoperative bradycardia and intraoperative and postoperative hypotension. The study was registered in the PROSPERO database under the identifier CRD420251001512. RESULTS: A total of 22 RCTs, involving 4161 patients, were included in the analysis. The results show that dexmedetomidine significantly reduced the incidence of POD (RR = 0.56, 95% CI: 0.47 to 0.66; P < 0.00001; I2 = 24%) and reduced PONV (RR = 0.79; 95% CI = 0.62 to 0.99; P = 0.04; I2 = 0%). Furthermore, dexmedetomidine was associated with a higher incidence of intraoperative and postoperative bradycardia as well as intraoperative hypotension. CONCLUSION: This meta-analysis suggests that dexmedetomidine reduces POD and PONV incidence in older surgical patients but increases intraoperative and postoperative bradycardia and intraoperative hypotension.

  3. Review Rev Esp Anestesiol Reanim (Engl Ed)Published 29 Oct 2026 Estefó M et al.
    Dexmedetomidine versus propofol for the prevention of postoperative delirium in older adults undergoing regional anaesthesia: A systematic review and meta-analysis.
    AI summary of the abstract, unverified
    • Systematic review and meta-analysis of five randomized trials, totaling 1613 adults aged 60 or older having surgery under regional anesthesia.
    • Compared intraoperative dexmedetomidine with propofol, with delirium assessed using CAM or CAM-ICU.
    • Delirium occurred in 7.7% of dexmedetomidine patients versus 16.7% with propofol (RR 0.48, 95% CI 0.36-0.64; P < .001), with low heterogeneity (I² = 13.4%).
    • The authors conclude dexmedetomidine is associated with less postoperative delirium, and they rated the certainty of evidence as moderate by GRADE.
    Original abstract (PubMed)

    Postoperative delirium (POD) is a common complication in older adults undergoing surgery and is associated with adverse clinical outcomes. The choice of intraoperative sedative may influence its occurrence, particularly in the setting of regional anesthesia. A systematic review and meta-analysis of randomized controlled trials comparing dexmedetomidine versus propofol in patients aged ≥60 years was conducted in accordance with PRISMA guidelines, with protocol registration in PROSPERO. The primary outcome was the incidence of POD assessed using validated instruments (CAM or CAM-ICU). Five randomized controlled trials involving a total of 1613 patients were included. The incidence of POD was 7.7% in the dexmedetomidine groups and 16.7% in the propofol groups. The meta-analysis showed a significant reduction in POD with dexmedetomidine (RR 0.48, 95% CI 0.36-0.64; P < .001), with low heterogeneity (I2 = 13.4%). Egger's test did not show significant evidence of publication bias, and trial sequential analysis suggested that the available evidence is sufficient. The certainty of evidence was rated as moderate according to the GRADE approach. In older adults undergoing surgery under regional anesthesia, intraoperative sedation with dexmedetomidine is associated with a lower incidence of POD compared with propofol.

  4. Review Diagnostics (Basel)Published 27 Oct 2026 Katona OB et al.
    Postoperative Delirium Across the Perioperative Pathway: A Structured Narrative Review of Clinical Maturity and Implementation Priorities.
    AI summary of the abstract, unverified
    • This structured narrative review synthesizes adult postoperative delirium evidence across the perioperative pathway, searching major databases plus ESAIC and ASA resources and reference lists.
    • It classifies prevention and therapeutic strategies by clinical maturity, target population, and implementation readiness rather than by pooled effect size.
    • The authors report that no single anesthetic technique, processed-EEG target, blood-pressure threshold, cerebral oximetry strategy, or agent consistently prevents delirium across surgical populations.
    • Multicomponent non-pharmacological prevention has the most consistent support, dexmedetomidine appears context-dependent, and biomarkers and metabolic targets remain investigational.
    Original abstract (PubMed)

    Postoperative delirium (POD) is a highly prevalent but frequently underrecognized complication that disproportionately affects frail and older surgical patients. This structured narrative review aims to synthesize contemporary evidence on adult postoperative delirium across the perioperative pathway and to classify major preventive and therapeutic strategies according to clinical maturity, target population, and implementation readiness. A structured literature search of PubMed/MEDLINE, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science Core Collection was performed, supplemented by ClinicalTrials.gov, official ESAIC and ASA resources, reference-list screening, and selected seminal pre-2021 publications. Current evidence supports a multifactorial model in which baseline cognitive and physiological vulnerability interacts with inflammatory, pharmacological, hemodynamic, nociceptive, sleep-related, and environmental stressors. No single anesthetic technique, processed-EEG target, blood-pressure threshold, cerebral oximetry strategy, or pharmacological agent consistently prevents POD across surgical populations. Multicomponent non-pharmacological prevention has the most consistent support, whereas dexmedetomidine and other pharmacological approaches appear context-dependent, and biomarkers and metabolic targets remain investigational. Future progress will depend on standardized delirium ascertainment, better phenotyping, multimodal prediction and prevention strategies, and reliable implementation systems that identify vulnerability early and maintain effective preventive care across transitions.

  5. Review Front PediatrPublished 21 Oct 2026 Yang Y et al.
    Dose- and endpoint-dependent effects of perioperative esketamine in children: evidence from a targeted review.
    AI summary of the abstract, unverified
    • This mini review synthesizes a targeted search of pediatric esketamine studies covering analgesia, sedation, propofol injection pain, and emergence delirium or agitation.
    • Randomized trials and meta-analyses generally report fewer emergence delirium or agitation events after low intravenous esketamine doses, mostly during sevoflurane adenotonsillectomy.
    • Direct dose-comparison evidence in that setting shows increasing benefit up to 0.5 mg/kg intravenously, with no upper efficacy or safety boundary identified.
    • The authors conclude that 0.2-0.5 mg/kg IV was the best-studied range for emergence prevention, not a validated therapeutic window, and call for direct dose-timing trials.
    Original abstract (PubMed)

    Esketamine is being evaluated for several paediatric perioperative indications, including analgesia, procedural sedation, attenuation of propofol injection pain, and prevention of emergence delirium (ED) or emergence agitation (EA). This mini review examines whether evidence identified in a targeted search supports a clinically useful therapeutic window and how dose, timing, route, developmental stage, anaesthetic technique, procedure, co-medication, and outcome definition modify treatment effects. Randomised trials and meta-analyses generally report fewer ED or EA events after low intravenous doses, particularly during sevoflurane anaesthesia for adenotonsillectomy. Direct dose-comparison evidence shows increasing benefit up to 0.5 mg·kg-1 intravenously in that setting, without identifying an upper efficacy or safety boundary. An observational association between esketamine exposure and more ED cannot establish a threshold because treatment selection and perioperative context were not controlled. Effective doses are endpoint-specific: propofol injection pain, procedural sedation, analgesia, and emergence outcomes require different exposure profiles. Intranasal regimens cannot be converted into intravenous equivalents from bioavailability alone, and preclinical neurotoxicity findings do not define a ceiling for a single perioperative dose in children. Among the studies identified, 0.2-0.5 mg·kg-1 was the best-studied intravenous range in selected emergence-prevention settings, not a universal recommendation or validated therapeutic window. Future trials should compare dose and timing directly, incorporate paediatric pharmacokinetic-pharmacodynamic sampling, use endpoint-specific assessment, and extend safety follow-up.

  6. Review Anaesth Crit Care Pain MedPublished 2 Oct 2026 Shin CCY et al.
    Effects of dexmedetomidine on postoperative outcomes in adult non-cardiac surgical patients admitted to the intensive care unit: a systematic review and network meta-analysis of randomized controlled trials.
    AI summary of the abstract, unverified
    • Systematic review and network meta-analysis of 24 RCTs (22 in the meta-analysis, 2,544 patients) in adults admitted to the ICU after non-cardiac surgery.
    • Compared dexmedetomidine with normal saline, midazolam, and propofol as postoperative sedation strategies, with ICU delirium as the primary outcome.
    • Dexmedetomidine may reduce delirium versus midazolam (RR 0.11, 95% CI 0.02 to 0.80; very low certainty) and versus normal saline (RR 0.46, 95% CI 0.36 to 0.59; low certainty).
    • No differences in extubation time or ICU length of stay across strategies, while bradycardia was probably more likely than with propofol (RR 3.03, 95% CI 1.39-6.25; low certainty).
    Original abstract (PubMed)

    BACKGROUND: The role of dexmedetomidine in patients admitted to the intensive care unit (ICU) following non-cardiac surgery remains unclear. While dexmedetomidine is widely used for its sedative and potential delirium-sparing properties, its pooled effects on clinically relevant postoperative outcomes in this population are not well established. This systematic review and network meta-analysis evaluated the comparative effectiveness and safety of dexmedetomidine compared with other sedative strategies in postoperative non-cardiac surgical ICU patients. METHODS: We systematically searched PubMed, Cochrane CENTRAL, and Embase from inception to 26 May 2026 for randomised controlled trials (RCTs) comparing postoperative dexmedetomidine with normal saline or other sedatives in adults (≥18 years) admitted to the ICU after non-cardiac surgery. The primary outcome was incidence of delirium during the ICU stay. Secondary outcomes were time to extubation, ICU length of stay, duration of mechanical ventilation, and haemodynamic adverse events. Effect estimates were expressed as relative risks (RRs) or mean differences (MDs) using random-effects models. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated using the GRADE framework. Interventions were ranked using the surface under the cumulative ranking curve (SUCRA) for each outcome. RESULTS: Twenty-four RCTs involving 2,777 patients were included in the systematic review, of which 22 RCTs involving 2,544 patients contributed to the network meta-analysis. Compared with midazolam (RR 0.11, 95% CI 0.02 to 0.80; very low certainty) and normal saline (RR 0.46, 95% CI 0.36 to 0.59; low certainty), dexmedetomidine may reduce the risk of delirium. Evidence is insufficient to determine whether propofol differs from dexmedetomidine in its effect on delirium. There were no differences in time to extubation, duration of mechanical ventilation, or ICU length of stay across sedative strategies. Dexmedetomidine probably increases the risk of bradycardia compared with propofol (RR 3.03, 95% CI 1.39-6.25; low certainty), but the evidence is insufficient to determine whether the two agents differ in their effects on hypotension. In safety rankings, dexmedetomidine performed least favourably for bradycardia (SUCRA 0.03) and hypotension (SUCRA 0.13). CONCLUSIONS: Dexmedetomidine may reduce postoperative delirium in non-cardiac surgical ICU patients but does not appear to improve ventilatory recovery or ICU length of stay and is associated with higher bradycardia risk. Its principal benefit lies in delirium prevention, supporting an individualised approach to sedative selection.

  7. Review Drug Des Devel TherPublished 16 Sep 2026 Qian H et al.
    Precision Sedation for Gastrointestinal Endoscopy in Older Adults: Brain Vulnerability and Recovery.
    AI summary of the abstract, unverified
    • This narrative-style review addresses sedation for gastrointestinal endoscopy in older adults, who face higher risks of oversedation, hypoxemia, and slow recovery.
    • It compares propofol with remimazolam, ciprofol, and dexmedetomidine, and describes monitoring tools such as processed EEG, cerebral oximetry, and capnography.
    • The abstract reports no pooled effect sizes or statistics; it argues that propofol's cardiorespiratory depression is dose dependent and that newer agents may offer stability in selected patients.
    • The authors conclude that sedation should target the minimum effective depth, and that better short-term cardiopulmonary outcomes should not be assumed to prevent delirium or cognitive decline.
    Original abstract (PubMed)

    Older adults undergoing gastrointestinal endoscopy are particularly susceptible to oversedation, hypotension, hypoventilation, hypoxemia, and delayed recovery because physiological and cognitive reserve decline with age. Precision sedation provides a practical approach to these problems by tailoring drug selection, dose titration, monitoring, and supportive measures to the individual patient and the requirements of the procedure. Propofol remains widely used because of its rapid onset and predictable recovery, although cardiorespiratory depression remains dose dependent. Remimazolam and ciprofol may offer greater hemodynamic or respiratory stability in selected patients, while dexmedetomidine and combination regimens can reduce exposure to other sedatives but introduce their own limitations. Monitoring with processed electroencephalography, cerebral oximetry, capnography, and routine hemodynamic assessment may help identify excessive sedation or physiological deterioration when findings are interpreted in clinical context. However, improvements in short-term cardiopulmonary outcomes or recovery should not be assumed to prevent postoperative delirium or longer-term cognitive impairment. In older adults, sedation should therefore aim for the minimum effective depth while avoiding excessive drug exposure and promptly correcting respiratory and circulatory disturbances. Further endoscopy-specific studies are needed to determine whether these strategies improve cognitive and functional recovery.

  8. Review Z Gerontol GeriatrPublished 25 Aug 2026 Thomas C et al.
    [Multicomponent programs in delirium prevention and delirium management in older adults : Evidence, guideline recommendations and perspectives on delirium-sensitive care].
    AI summary of the abstract, unverified
    • This is a review of delirium prevention and management evidence and the German S3 guideline in older adults, and it gives no sample size.
    • It contrasts nonpharmacological multicomponent programs (HELP, ABCDE(F), CHOPS, AKTIVER) with pharmacological strategies.
    • It cites two 2026 meta-analyses reporting a 44% reduction in delirium incidence and shorter duration once delirium was established; drug benefits were inconsistent or limited.
    • The authors conclude that the S3 guideline strongly recommends structured, interdisciplinary, person-centered programs, and only dexmedetomidine showed a preventive effect in selected perioperative settings.
    Original abstract (PubMed)

    Delirium is among the most frequent neuropsychiatric complications in older people. It is associated with functional decline, increased morbidity and mortality, loss of independence, cognitive deterioration and an elevated risk of dementia. Contemporary concepts view delirium as the result of an interplay between predisposing vulnerability factors and acute physiological stressors. Current approaches to delirium prevention and management focus on nonpharmacological multicomponent interventions that combine early mobilization, cognitive reorientation, sleep hygiene, pain management, optimization of nutrition and hydration, delirium screening and family involvement. Programs such as HELP, ABCDE(F) bundle, CHOPS and AKTIVER have shaped the development of evidence-based delirium prevention. The strongest evidence to date derives from two meta-analyses published in 2026. In these studies, nonpharmacological multicomponent programs reduced delirium incidence by 44% and significantly shortened delirium duration in patients with established delirium. In contrast, pharmacological strategies demonstrated inconsistent or limited benefits. Only dexmedetomidine showed a preventive effect in selected perioperative settings. The current German S3 guidelines "Delirium in older age" therefore strongly recommend structured, interdisciplinary and person-centered delirium programs. Future challenges include comprehensive implementation, the development of specialized concepts for high-risk populations, improved cross-sectoral care pathways and the meaningful integration of digital technologies. A delirium-sensitive hospital culture should become a key quality indicator not only in geriatric medicine but also in inpatient care across all clinical disciplines.

Earlier evidence / dates not confirmed

Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.

  1. No matching papers in this section with the selected filters.

Ongoing registrations

From ClinicalTrials.gov

Registrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.

No registered ongoing trials found.